{"ticker": {"uuid": "fb9d116e-ec5e-4a26-85b5-963b7ccfb38d", "symbol": "LXEO", "name": "Lexeo Therapeutics, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple", "summary": "Lexeo Therapeutics (LXEO) is highlighted as a top stock under $10 with the potential to triple, following the finalization of its critical trial protocol for SUNRISE-FA 2 and statistical analysis plan for LX2006, a gene-based therapy for Friedreich's ataxia cardiomyopathy. Despit", "url": "https://finance.yahoo.com/markets/stocks/articles/makes-lexeo-therapeutics-lxeo-one-154304169.html", "source_name": "Market source", "published_at": "2026-07-15T15:42:57", "published_display": "15 Jul 2026 15:42", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "LXEO News | LEXEO THERAPEUTICS INC (NASDAQ:LXEO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE9iWF9fU0R0WFZ5VGJIY25yLWpvSjQzQU5MTzdCR3JhYUxObUpZem11TjFsWFlqdkVvUGRFLV9JcHB4NS1sR2NMNWhhOHRnY29YNjRSY2gxdHNfNWM?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:15:14+00:00", "published_display": "11 Jul 2026 00:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (Nasdaq:LXEO) - Stock Analysis", "summary": "Lexeo Therapeutics (LXEO), a clinical-stage genetic medicine company, is currently unprofitable and trading below its estimated fair value with projected revenue growth of 65.61% per year. The company's primary focus is LX2006 for Friedreich's ataxia (FA) cardiomyopathy, which ha", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxeo/lexeo-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-07-10T06:40:43", "published_display": "10 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (NasdaqGM:LXEO) Stock Forecast & Analyst Predictions", "summary": "Lexeo Therapeutics (NasdaqGM:LXEO) is projected to experience significant growth in earnings and revenue, with analysts forecasting 48.9% and 65.6% increases per annum, respectively. The company is advancing its gene therapy LX2006 for Friedreich's ataxia cardiomyopathy, with piv", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxeo/lexeo-therapeutics/future", "source_name": "Simply Wall Street", "published_at": "2026-07-08T07:41:42", "published_display": "08 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LXEO - Lexeo Therapeutics Inc Dividends", "summary": "This page provides a detailed financial overview of Lexeo Therapeutics Inc. (LXEO), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, insider ownership, institutional ownersh", "url": "https://finviz.com/stock?t=LXEO&ta=1&p=d&ty=dv&b=2", "source_name": "Finviz", "published_at": "2026-07-05T04:40:43", "published_display": "05 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Lexeo Therapeutics Insiders Been Selling Stock?", "summary": "The article \"Have Lexeo Therapeutics Insiders Been Selling Stock?\" provides an analysis of insider trading activity at Lexeo Therapeutics. It reviews recent transactions to determine if company insiders have been buying or selling shares. The article aims to shed light on how tho", "url": "https://news.futunn.com/en/post/75518498/have-lexeo-therapeutics-insiders-been-selling-stock", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-04T06:10:27", "published_display": "04 Jul 2026 06:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Insiders Sold Lexeo Therapeutics Shares Recently?", "summary": "Lexeo Therapeutics' Chief Medical Officer, Narinder Bhalla, recently sold US$99k worth of stock, reducing their holding by 21%. This follows a larger sale by the CEO & Director, R. Townsend, for US$117k in the last year, though that transaction was at a higher price than current ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxeo/lexeo-therapeutics/news/have-insiders-sold-lexeo-therapeutics-shares-recently", "source_name": "Simply Wall Street", "published_at": "2026-07-03T11:40:55", "published_display": "03 Jul 2026 11:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Lexeo Therapeutics, Inc. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Lexeo Therapeutics, Inc. (LXEO) on July 1, 2026. The filing indicates a proposed sale of 22,306 shares of common stock with an aggregate market value of $98,683.97, acquired on June 29, 2026, through restricted stock vesting. The s", "url": "https://www.stocktitan.net/sec-filings/LXEO/144-lexeo-therapeutics-inc-sec-filing-f21093cd6f36.html", "source_name": "Stock Titan", "published_at": "2026-07-02T18:11:59", "published_display": "02 Jul 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update?", "summary": "JPMorgan recently lowered its price target for Lexeo Therapeutics, Inc. (LXEO) to $9 from $12 but maintained an Overweight rating, based on an updated valuation model. Lexeo also announced the completion of the SUNRISE-FA 2 pivotal trial protocol for its gene therapy candidate LX", "url": "https://www.insidermonkey.com/blog/is-lexeo-therapeutics-inc-lxeo-stock-still-a-gene-therapy-opportunity-after-analyst-valuation-update-1793955/", "source_name": "Insider Monkey", "published_at": "2026-07-02T16:06:00", "published_display": "02 Jul 2026 16:06", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (LXEO) COO reports stock award and small tax-related sale", "summary": "Lexeo Therapeutics' Chief Operating Officer, Jose Manuel Otero, reported receiving a stock grant of 12,060 shares on June 29 and subsequently selling 4,666 shares on July 1 to cover tax obligations related to the vesting of performance Restricted Stock Units (RSUs). After these t", "url": "https://www.stocktitan.net/sec-filings/LXEO/form-4-lexeo-therapeutics-inc-insider-trading-activity-b5e5ee9ba571.html", "source_name": "Stock Titan", "published_at": "2026-07-02T03:09:53", "published_display": "02 Jul 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics CMO sells $98,592 in shares By Investing.com", "summary": "Lexeo Therapeutics' Chief Medical Officer, Narinder Pal Bhalla, sold 22,306 shares of common stock for $98,592 to cover tax obligations from Restricted Stock Units. This transaction occurred after acquiring 55,000 shares at $0.00 and leaves him with 82,194 shares. The company is ", "url": "https://ca.investing.com/news/stock-market-news/lexeo-therapeutics-cmo-sells-98592-in-shares-93CH-4717328", "source_name": "Investing.com Canada", "published_at": "2026-07-02T00:09:53", "published_display": "02 Jul 2026 00:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics CMO sells $98,592 in shares", "summary": "Narinder Pal Bhalla, CMO of Lexeo Therapeutics (NASDAQ:LXEO), sold 22,306 shares totaling $98,592 to cover tax obligations from RSU releases. This transaction follows an acquisition of 55,000 shares on June 29, 2026, and leaves Mr. Bhalla with 82,194 shares. The company is active", "url": "https://www.investing.com/news/insider-trading-news/lexeo-therapeutics-cmo-sells-98592-in-shares-93CH-4771987", "source_name": "Investing.com", "published_at": "2026-07-01T23:15:29", "published_display": "01 Jul 2026 23:15", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics COO Otero sells $20,903 in LXEO stock", "summary": "Lexeo Therapeutics COO Jose Manuel Otero sold 4,666 shares of LXEO stock for $20,903 to cover tax obligations. The stock is currently trading at $4.45, down 55% over the past six months. The company recently published Phase I/II study results for its gene therapy LX2006 for Fried", "url": "https://www.investing.com/news/insider-trading-news/lexeo-therapeutics-coo-otero-sells-20903-in-lxeo-stock-93CH-4771986", "source_name": "Investing.com", "published_at": "2026-07-01T23:15:29", "published_display": "01 Jul 2026 23:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RSU grant and tax-cover share sale by Lexeo (LXEO) chief financial officer", "summary": "Lexeo Therapeutics' Chief Financial Officer, Louis Edward Tamayo, reported an award of 12,000 shares of common stock and subsequently sold 4,641 shares at a weighted average price of $4.49 each. This sale was explicitly made to cover tax obligations arising from the vesting of pe", "url": "https://www.stocktitan.net/sec-filings/LXEO/form-4-lexeo-therapeutics-inc-insider-trading-activity-bb86ac059861.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:09:54", "published_display": "01 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (LXEO) CEO logs RSU grant and tax-driven share sale", "summary": "Richard Nolan Townsend, CEO of Lexeo Therapeutics, reported two equity transactions: a grant of 67,000 shares on June 29, 2026, and the sale of 25,947 shares on July 1, 2026, at a weighted average price of $4.48. The sale was specifically to cover tax obligations from vested Rest", "url": "https://www.stocktitan.net/sec-filings/LXEO/form-4-lexeo-therapeutics-inc-insider-trading-activity-252933b72a63.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:09:53", "published_display": "01 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (LXEO) CMO awarded 55K shares and sells 22K to cover RSU taxes", "summary": "Lexeo Therapeutics' Chief Medical Officer, Narinder Pal Bhalla, received a grant of 55,000 common shares on June 29, 2026, as part of his compensation. To cover tax obligations related to the release of performance Restricted Stock Units (RSUs), Bhalla subsequently sold 22,306 sh", "url": "https://www.stocktitan.net/sec-filings/LXEO/form-4-lexeo-therapeutics-inc-insider-trading-activity-d44946d81d35.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:09:53", "published_display": "01 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics COO Otero sells $20,903 in LXEO stock By Investing.com", "summary": "Lexeo Therapeutics COO Jose Manuel Otero sold 4,666 shares of LXEO stock for $20,903 to cover tax obligations from vested RSUs. This transaction occurred on July 1, 2026, with shares sold at a weighted average price of $4.48. Otero still directly holds 137,482 shares, including R", "url": "https://ca.investing.com/news/stock-market-news/lexeo-therapeutics-coo-otero-sells-20903-in-lxeo-stock-93CH-4717330", "source_name": "Investing.com Canada", "published_at": "2026-07-01T23:09:53", "published_display": "01 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Lexeo Therapeutics Inc For: 1 July By Investing.com", "summary": "This article reports on the filing of Form 4 for Lexeo Therapeutics Inc. on July 1st. It also includes general market data, popular news headlines from Investing.com, and various market indices and commodity prices. The content primarily focuses on financial markets and company n", "url": "https://ca.investing.com/news/stock-market-news/form-4-lexeo-therapeutics-inc-for-1-july-93CH-4717332", "source_name": "Investing.com Canada", "published_at": "2026-07-01T23:09:53", "published_display": "01 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LXEO (NASDAQ: LXEO) director files Form 144 proposing sale of 25,947 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxONmNKaDEtMjFZWTl4V0JweVk4R1VsRnNZZXc1MkxKSXpsRHlWSGVOeHIxUnBLdUpENE5XVzB6VUxVYy1qMlVXMU1zc3A0ejdyRkF5SDJfOVRSU2hldjlvcXk5Ri16U01qTnVyWEl6TWx6aXFZMjF1RzJDeGl1RElneGNUbmxEUnpzeDFFWUdPRGJvOHgtSHU4MUlhV3RmQzRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T20:42:25+00:00", "published_display": "01 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LXEO (NASDAQ) Form 144: Proposed resale of 4,666 vested shares via Fidelity", "summary": "Lexeo Therapeutics, Inc. (LXEO) has filed a Form 144 notice indicating a proposed resale of 4,666 common shares through Fidelity Brokerage Services LLC. These shares are linked to a restricted stock vesting event that occurred on June 29, 2026, as compensation. The filing is proc", "url": "https://www.stocktitan.net/sec-filings/LXEO/144-lexeo-therapeutics-inc-sec-filing-1d8bed3407e5.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:15:29", "published_display": "01 Jul 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (LXEO) director awarded 35,000 stock options at $4.70", "summary": "Lexeo Therapeutics director Brenda Cooperstone was granted 35,000 stock options with an exercise price of $4.70 per share, expiring on June 24, 2036. The options will vest one year after the grant date or at the next annual meeting, provided she maintains continuous service. This", "url": "https://www.stocktitan.net/sec-filings/LXEO/form-4-lexeo-therapeutics-inc-insider-trading-activity-d834b77d5dfb.html", "source_name": "Stock Titan", "published_at": "2026-06-30T02:11:41", "published_display": "30 Jun 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Lexeo Therapeutics Inc For: 29 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Lexeo Therapeutics Inc., indicating insider trading activity. The filing pertains to actions taken on June 29 and is a standard regulatory disclosure for public companies. The article provides only this brief detail w", "url": "https://ng.investing.com/news/stock-market-news/form-4-lexeo-therapeutics-inc-for-29-june-93CH-2578889", "source_name": "Investing.com Nigeria", "published_at": "2026-06-29T21:46:00", "published_display": "29 Jun 2026 21:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (LXEO) director awarded options on 35,000 shares at $4.70", "summary": "Lexeo Therapeutics director Steven Altschuler was granted options for 35,000 shares of common stock at an exercise price of $4.70 per share, expiring on June 24, 2036. The options will vest either one year after the grant date or at the next annual stockholders' meeting, provided", "url": "https://www.stocktitan.net/sec-filings/LXEO/form-4-lexeo-therapeutics-inc-insider-trading-activity-ea5721f52713.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:11:41", "published_display": "29 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (NASDAQ: LXEO) investors approve directors and ratify KPMG auditor", "summary": "Lexeo Therapeutics, Inc. (NASDAQ: LXEO) shareholders approved the election of three Class III directors\u2014R. Nolan Townsend, Brenda Cooperstone, M.D., and Paula HJ Cholmondeley\u2014to serve until the 2029 annual meeting. Additionally, stockholders ratified the appointment of KPMG LLP a", "url": "https://www.stocktitan.net/sec-filings/LXEO/8-k-lexeo-therapeutics-inc-reports-material-event-4cb86241e17d.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:39:55", "published_display": "29 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (LXEO) director receives grant of 35,000 stock options at $4.70", "summary": "Lexeo Therapeutics, Inc. director Paula H. Cholmondeley was granted 35,000 stock options at an exercise price of $4.70 per share, expiring on June 24, 2036. The options will vest on the earlier of one year after the grant date or the next annual stockholders' meeting, subject to ", "url": "https://www.stocktitan.net/sec-filings/LXEO/form-4-lexeo-therapeutics-inc-insider-trading-activity-eb3a7700c7e8.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:11:41", "published_display": "29 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (LXEO) director receives 35,000 options at $4.70", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQYWUzaDVqVXVLd1N4RXlESTgwOWkxM21vM0RaVlcwdXQ0YW8yamV3UU1XU1FLbWx4ZDJya1hXakVlVWszMnQtV1NEdDZwSHpJb3dxWEhXMmxtUmNsM05tRGhiSUhzaGN5d013NlVXLUVMZElxeWVGZU9QLTFSTmRZcy0xQlByMTdfcW0xYXd1VDRBYk9CMy1TazlWa0VWTlBiYUVubkJDc3lvU1lkbTdkZHZJYTVTRnM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (LXEO) director awarded 35,000 stock options at $4.70 strike", "summary": "Lexeo Therapeutics director Reinaldo M. Diaz was granted 35,000 stock options at an exercise price of $4.70 per share as equity compensation. These options will vest on the earlier of one year from the grant date or the next annual stockholders' meeting, conditional on his contin", "url": "https://www.stocktitan.net/sec-filings/LXEO/form-4-lexeo-therapeutics-inc-insider-trading-activity-cc2a4bf91386.html", "source_name": "Stock Titan", "published_at": "2026-06-28T06:40:43", "published_display": "28 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Price Target Cut to $9.00/Share From $12.00 by JP Morgan", "summary": "JP Morgan has adjusted its price target for Lexeo Therapeutics, lowering it from $12.00 per share to $9.00 per share.", "url": "https://www.moomoo.com/news/post/72046425/lexeo-therapeutics-price-target-cut-to-9-00-share-from", "source_name": "Moomoo", "published_at": "2026-06-26T13:08:54", "published_display": "26 Jun 2026 13:08", "sentiment": "negative", "sentiment_pct": 24, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Lexeo Therapeutics, Inc. \u2013 NASDAQ:LXEO", "summary": "This article displays the \"Price to sales forward\" metric for Lexeo Therapeutics, Inc. under the NASDAQ:LXEO ticker. It presents a financial overview of the company on the TradingView platform, showing the period, value, change, and percentage change for this specific financial i", "url": "https://www.tradingview.com/symbols/NASDAQ-LXEO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:39:42", "published_display": "26 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Is Maintained at Overweight by JP Morgan", "summary": "JP Morgan has reiterated its \"Overweight\" rating on Lexeo Therapeutics. The article states that this is a maintenance of a previous rating. No further details about the reasons behind the rating or the company's performance are provided.", "url": "https://www.moomoo.com/news/post/72046428/lexeo-therapeutics-is-maintained-at-overweight-by-jp-morgan", "source_name": "Moomoo", "published_at": "2026-06-26T01:39:29", "published_display": "26 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/lexeo-therapeutics-announces-publication-jama-200100504.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T20:01:00+00:00", "published_display": "17 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Finalizes Study Design for Friedreich Ataxia Gene Therapy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexeo-therapeutics-finalizes-study-design-132952545.html", "source_name": "MT Newswires", "published_at": "2026-06-15T13:29:52+00:00", "published_display": "15 Jun 2026 13:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexeo-therapeutics-announces-regulatory-registrational-110000889.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T11:00:00+00:00", "published_display": "15 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (Nasdaq: LXEO) maps LX2006 pivotal trial, 2027 data and 2028 BLA bid", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNc0dkc1Q2OS1jUXc1ZUFTTzR1WnpCZnZXMUU2em5JazY3SWIxbW5qbXppUlprN2ZEbG0ydVhHVkdyYWFYeXl3ZkVLMXRWS0lIUVNuUjU1cmNTREdJeDVrT2p1Sk0yS1dMSUhFcElLM2J5N0xJNnltTDY0VTc0bGpUeHVlUlJaRXFRbHZ2bjRTSXptTEVyeEF6R1hVVnVOLXVlR0lKS19VbnNZY19JOUZocw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexeo-therapeutics-participate-2026-rbc-110000578.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T11:00:00+00:00", "published_display": "19 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexeo-therapeutics-reports-first-quarter-110000012.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T11:00:00+00:00", "published_display": "11 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexeo-therapeutics-announces-multiple-presentations-211500887.html", "source_name": "GlobeNewswire", "published_at": "2026-04-27T21:15:00+00:00", "published_display": "27 Apr 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$LXEO stock is up 9% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOendQODZkMnNTSm5BWlQwcFhUcy15MzN4cm56ZzJha1JTUmlja1hIdXUtOEJaVk5mQUhVOFktR2dOMHMxdjdBTGZHWGVCUFY1Z3J5YzhRQ3ZBS0ltVl9PN1JFYjgxd0FvQmlYRWtGakxGMENSVWttTWZudUQwaTB5WTRPZ2FmY0xfSEVYbEFRZFRUT2NwaTRuZFR6Y0VwWWM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn\u2019t the Only Problem.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPMTdzUkZQWG9tTW9zT3FxSWtzdkdLLUNYVkRJMDh2X1VRSlVrdmVkS3FCSVFpX210VUxVSUF1Q2FYakw1ZUxyQlpoZHZpM1RYQzBOYlpEWENxeGM1bXBZNFYxQjZRcFBpcS0tVVhRdzFTejBrVzU3aU9QQXdnYkZBMWxB?oc=5", "source_name": "Barron's", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional investors have a lot riding on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with 56% ownership", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-10T08:00:00+00:00", "published_display": "10 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Announces $80 Million Equity Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgJBVV95cUxQSkZmVWNXWE51TFg4NWwxQnMyVWVmbFdRSnZLZFlNb1RJTU93dXVxbWRfUjg1czhaUzVlRzRUTENjUjNINkE3OWJoWmVYNWZnZkVCaUJEcktNQ2pVUkFnUWRZUm1sSHdqRkNkWEZnWGtkLURlNWpTVlhWdFdpbWlNY3VxVEJ2aVZRd1JCTHoyWmQzYlNlWTNnd0FTRlBLTVNaaXgySm5wdXlJN0s4dlVwQjg0RTJxemNoeW5ieC1qaE5XZDJteEg5RU5YOVhSczJSOEtnYk9uUGJNdGhJS2tIU3ZfcXZzcGRSWkNPUWEtVFd4d3E1cWVVR1pEMUF0UUVGQ3Bzdkc5UmlRTUYySF9PcFlEa012NUdEYU1MOEhOMkIzTm9qVm5Nc1Fsc180RW9NM2NOcGsydFBwbGlhbzJ0WEZTQWRmdw?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-05-27T07:00:00+00:00", "published_display": "27 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNMW54UkNUOTN0ZUlqUF9GcFVxa3pNd2lGTncySXhYYjM3eUJoNUZOYzEtMFUzcmhfOWQzZlg5Q2VReEwxRWNzamxfWGxkaHBzbzEyWjU2ald3VVhkT2UwY0gtRV8zQmlWYi1JbnpTTlJQeEJtR3p0MUNGdVVHQkp3aFFGU2dnc0JTUGVvai00ekVwVlRQNjV2bGd4Wms4alZoWmQ1bUlTcHY3RTR3VXFHSlNfY081YXloZHlIbnlVaw?oc=5", "source_name": "Stock Titan", "published_at": "2024-03-13T07:00:00+00:00", "published_display": "13 Mar 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple", "summary": "Lexeo Therapeutics (LXEO) is highlighted as a top stock under $10 with the potential to triple, following the finalization of its critical trial protocol for SUNRISE-FA 2 and statistical analysis plan for LX2006, a gene-based therapy for Friedreich's ataxia cardiomyopathy. Despit", "url": "https://finance.yahoo.com/markets/stocks/articles/makes-lexeo-therapeutics-lxeo-one-154304169.html", "source_name": "Market source", "published_at": "2026-07-15T15:42:57", "published_display": "15 Jul 2026 15:42", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LXEO News | LEXEO THERAPEUTICS INC (NASDAQ:LXEO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE9iWF9fU0R0WFZ5VGJIY25yLWpvSjQzQU5MTzdCR3JhYUxObUpZem11TjFsWFlqdkVvUGRFLV9JcHB4NS1sR2NMNWhhOHRnY29YNjRSY2gxdHNfNWM?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:15:14+00:00", "published_display": "11 Jul 2026 00:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (Nasdaq:LXEO) - Stock Analysis", "summary": "Lexeo Therapeutics (LXEO), a clinical-stage genetic medicine company, is currently unprofitable and trading below its estimated fair value with projected revenue growth of 65.61% per year. The company's primary focus is LX2006 for Friedreich's ataxia (FA) cardiomyopathy, which ha", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxeo/lexeo-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-07-10T06:40:43", "published_display": "10 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (NasdaqGM:LXEO) Stock Forecast & Analyst Predictions", "summary": "Lexeo Therapeutics (NasdaqGM:LXEO) is projected to experience significant growth in earnings and revenue, with analysts forecasting 48.9% and 65.6% increases per annum, respectively. The company is advancing its gene therapy LX2006 for Friedreich's ataxia cardiomyopathy, with piv", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxeo/lexeo-therapeutics/future", "source_name": "Simply Wall Street", "published_at": "2026-07-08T07:41:42", "published_display": "08 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LXEO - Lexeo Therapeutics Inc Dividends", "summary": "This page provides a detailed financial overview of Lexeo Therapeutics Inc. (LXEO), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, insider ownership, institutional ownersh", "url": "https://finviz.com/stock?t=LXEO&ta=1&p=d&ty=dv&b=2", "source_name": "Finviz", "published_at": "2026-07-05T04:40:43", "published_display": "05 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Lexeo Therapeutics Insiders Been Selling Stock?", "summary": "The article \"Have Lexeo Therapeutics Insiders Been Selling Stock?\" provides an analysis of insider trading activity at Lexeo Therapeutics. It reviews recent transactions to determine if company insiders have been buying or selling shares. The article aims to shed light on how tho", "url": "https://news.futunn.com/en/post/75518498/have-lexeo-therapeutics-insiders-been-selling-stock", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-04T06:10:27", "published_display": "04 Jul 2026 06:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Insiders Sold Lexeo Therapeutics Shares Recently?", "summary": "Lexeo Therapeutics' Chief Medical Officer, Narinder Bhalla, recently sold US$99k worth of stock, reducing their holding by 21%. This follows a larger sale by the CEO & Director, R. Townsend, for US$117k in the last year, though that transaction was at a higher price than current ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxeo/lexeo-therapeutics/news/have-insiders-sold-lexeo-therapeutics-shares-recently", "source_name": "Simply Wall Street", "published_at": "2026-07-03T11:40:55", "published_display": "03 Jul 2026 11:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Lexeo Therapeutics, Inc. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Lexeo Therapeutics, Inc. (LXEO) on July 1, 2026. The filing indicates a proposed sale of 22,306 shares of common stock with an aggregate market value of $98,683.97, acquired on June 29, 2026, through restricted stock vesting. The s", "url": "https://www.stocktitan.net/sec-filings/LXEO/144-lexeo-therapeutics-inc-sec-filing-f21093cd6f36.html", "source_name": "Stock Titan", "published_at": "2026-07-02T18:11:59", "published_display": "02 Jul 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update?", "summary": "JPMorgan recently lowered its price target for Lexeo Therapeutics, Inc. (LXEO) to $9 from $12 but maintained an Overweight rating, based on an updated valuation model. Lexeo also announced the completion of the SUNRISE-FA 2 pivotal trial protocol for its gene therapy candidate LX", "url": "https://www.insidermonkey.com/blog/is-lexeo-therapeutics-inc-lxeo-stock-still-a-gene-therapy-opportunity-after-analyst-valuation-update-1793955/", "source_name": "Insider Monkey", "published_at": "2026-07-02T16:06:00", "published_display": "02 Jul 2026 16:06", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (LXEO) COO reports stock award and small tax-related sale", "summary": "Lexeo Therapeutics' Chief Operating Officer, Jose Manuel Otero, reported receiving a stock grant of 12,060 shares on June 29 and subsequently selling 4,666 shares on July 1 to cover tax obligations related to the vesting of performance Restricted Stock Units (RSUs). After these t", "url": "https://www.stocktitan.net/sec-filings/LXEO/form-4-lexeo-therapeutics-inc-insider-trading-activity-b5e5ee9ba571.html", "source_name": "Stock Titan", "published_at": "2026-07-02T03:09:53", "published_display": "02 Jul 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics CMO sells $98,592 in shares By Investing.com", "summary": "Lexeo Therapeutics' Chief Medical Officer, Narinder Pal Bhalla, sold 22,306 shares of common stock for $98,592 to cover tax obligations from Restricted Stock Units. This transaction occurred after acquiring 55,000 shares at $0.00 and leaves him with 82,194 shares. The company is ", "url": "https://ca.investing.com/news/stock-market-news/lexeo-therapeutics-cmo-sells-98592-in-shares-93CH-4717328", "source_name": "Investing.com Canada", "published_at": "2026-07-02T00:09:53", "published_display": "02 Jul 2026 00:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics CMO sells $98,592 in shares", "summary": "Narinder Pal Bhalla, CMO of Lexeo Therapeutics (NASDAQ:LXEO), sold 22,306 shares totaling $98,592 to cover tax obligations from RSU releases. This transaction follows an acquisition of 55,000 shares on June 29, 2026, and leaves Mr. Bhalla with 82,194 shares. The company is active", "url": "https://www.investing.com/news/insider-trading-news/lexeo-therapeutics-cmo-sells-98592-in-shares-93CH-4771987", "source_name": "Investing.com", "published_at": "2026-07-01T23:15:29", "published_display": "01 Jul 2026 23:15", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics COO Otero sells $20,903 in LXEO stock", "summary": "Lexeo Therapeutics COO Jose Manuel Otero sold 4,666 shares of LXEO stock for $20,903 to cover tax obligations. The stock is currently trading at $4.45, down 55% over the past six months. The company recently published Phase I/II study results for its gene therapy LX2006 for Fried", "url": "https://www.investing.com/news/insider-trading-news/lexeo-therapeutics-coo-otero-sells-20903-in-lxeo-stock-93CH-4771986", "source_name": "Investing.com", "published_at": "2026-07-01T23:15:29", "published_display": "01 Jul 2026 23:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RSU grant and tax-cover share sale by Lexeo (LXEO) chief financial officer", "summary": "Lexeo Therapeutics' Chief Financial Officer, Louis Edward Tamayo, reported an award of 12,000 shares of common stock and subsequently sold 4,641 shares at a weighted average price of $4.49 each. This sale was explicitly made to cover tax obligations arising from the vesting of pe", "url": "https://www.stocktitan.net/sec-filings/LXEO/form-4-lexeo-therapeutics-inc-insider-trading-activity-bb86ac059861.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:09:54", "published_display": "01 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (LXEO) CEO logs RSU grant and tax-driven share sale", "summary": "Richard Nolan Townsend, CEO of Lexeo Therapeutics, reported two equity transactions: a grant of 67,000 shares on June 29, 2026, and the sale of 25,947 shares on July 1, 2026, at a weighted average price of $4.48. The sale was specifically to cover tax obligations from vested Rest", "url": "https://www.stocktitan.net/sec-filings/LXEO/form-4-lexeo-therapeutics-inc-insider-trading-activity-252933b72a63.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:09:53", "published_display": "01 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (LXEO) CMO awarded 55K shares and sells 22K to cover RSU taxes", "summary": "Lexeo Therapeutics' Chief Medical Officer, Narinder Pal Bhalla, received a grant of 55,000 common shares on June 29, 2026, as part of his compensation. To cover tax obligations related to the release of performance Restricted Stock Units (RSUs), Bhalla subsequently sold 22,306 sh", "url": "https://www.stocktitan.net/sec-filings/LXEO/form-4-lexeo-therapeutics-inc-insider-trading-activity-d44946d81d35.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:09:53", "published_display": "01 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics COO Otero sells $20,903 in LXEO stock By Investing.com", "summary": "Lexeo Therapeutics COO Jose Manuel Otero sold 4,666 shares of LXEO stock for $20,903 to cover tax obligations from vested RSUs. This transaction occurred on July 1, 2026, with shares sold at a weighted average price of $4.48. Otero still directly holds 137,482 shares, including R", "url": "https://ca.investing.com/news/stock-market-news/lexeo-therapeutics-coo-otero-sells-20903-in-lxeo-stock-93CH-4717330", "source_name": "Investing.com Canada", "published_at": "2026-07-01T23:09:53", "published_display": "01 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Lexeo Therapeutics Inc For: 1 July By Investing.com", "summary": "This article reports on the filing of Form 4 for Lexeo Therapeutics Inc. on July 1st. It also includes general market data, popular news headlines from Investing.com, and various market indices and commodity prices. The content primarily focuses on financial markets and company n", "url": "https://ca.investing.com/news/stock-market-news/form-4-lexeo-therapeutics-inc-for-1-july-93CH-4717332", "source_name": "Investing.com Canada", "published_at": "2026-07-01T23:09:53", "published_display": "01 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LXEO (NASDAQ: LXEO) director files Form 144 proposing sale of 25,947 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxONmNKaDEtMjFZWTl4V0JweVk4R1VsRnNZZXc1MkxKSXpsRHlWSGVOeHIxUnBLdUpENE5XVzB6VUxVYy1qMlVXMU1zc3A0ejdyRkF5SDJfOVRSU2hldjlvcXk5Ri16U01qTnVyWEl6TWx6aXFZMjF1RzJDeGl1RElneGNUbmxEUnpzeDFFWUdPRGJvOHgtSHU4MUlhV3RmQzRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T20:42:25+00:00", "published_display": "01 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LXEO (NASDAQ) Form 144: Proposed resale of 4,666 vested shares via Fidelity", "summary": "Lexeo Therapeutics, Inc. (LXEO) has filed a Form 144 notice indicating a proposed resale of 4,666 common shares through Fidelity Brokerage Services LLC. These shares are linked to a restricted stock vesting event that occurred on June 29, 2026, as compensation. The filing is proc", "url": "https://www.stocktitan.net/sec-filings/LXEO/144-lexeo-therapeutics-inc-sec-filing-1d8bed3407e5.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:15:29", "published_display": "01 Jul 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (LXEO) director awarded 35,000 stock options at $4.70", "summary": "Lexeo Therapeutics director Brenda Cooperstone was granted 35,000 stock options with an exercise price of $4.70 per share, expiring on June 24, 2036. The options will vest one year after the grant date or at the next annual meeting, provided she maintains continuous service. This", "url": "https://www.stocktitan.net/sec-filings/LXEO/form-4-lexeo-therapeutics-inc-insider-trading-activity-d834b77d5dfb.html", "source_name": "Stock Titan", "published_at": "2026-06-30T02:11:41", "published_display": "30 Jun 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Lexeo Therapeutics Inc For: 29 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Lexeo Therapeutics Inc., indicating insider trading activity. The filing pertains to actions taken on June 29 and is a standard regulatory disclosure for public companies. The article provides only this brief detail w", "url": "https://ng.investing.com/news/stock-market-news/form-4-lexeo-therapeutics-inc-for-29-june-93CH-2578889", "source_name": "Investing.com Nigeria", "published_at": "2026-06-29T21:46:00", "published_display": "29 Jun 2026 21:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (LXEO) director awarded options on 35,000 shares at $4.70", "summary": "Lexeo Therapeutics director Steven Altschuler was granted options for 35,000 shares of common stock at an exercise price of $4.70 per share, expiring on June 24, 2036. The options will vest either one year after the grant date or at the next annual stockholders' meeting, provided", "url": "https://www.stocktitan.net/sec-filings/LXEO/form-4-lexeo-therapeutics-inc-insider-trading-activity-ea5721f52713.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:11:41", "published_display": "29 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (NASDAQ: LXEO) investors approve directors and ratify KPMG auditor", "summary": "Lexeo Therapeutics, Inc. (NASDAQ: LXEO) shareholders approved the election of three Class III directors\u2014R. Nolan Townsend, Brenda Cooperstone, M.D., and Paula HJ Cholmondeley\u2014to serve until the 2029 annual meeting. Additionally, stockholders ratified the appointment of KPMG LLP a", "url": "https://www.stocktitan.net/sec-filings/LXEO/8-k-lexeo-therapeutics-inc-reports-material-event-4cb86241e17d.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:39:55", "published_display": "29 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (LXEO) director receives grant of 35,000 stock options at $4.70", "summary": "Lexeo Therapeutics, Inc. director Paula H. Cholmondeley was granted 35,000 stock options at an exercise price of $4.70 per share, expiring on June 24, 2036. The options will vest on the earlier of one year after the grant date or the next annual stockholders' meeting, subject to ", "url": "https://www.stocktitan.net/sec-filings/LXEO/form-4-lexeo-therapeutics-inc-insider-trading-activity-eb3a7700c7e8.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:11:41", "published_display": "29 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (LXEO) director receives 35,000 options at $4.70", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQYWUzaDVqVXVLd1N4RXlESTgwOWkxM21vM0RaVlcwdXQ0YW8yamV3UU1XU1FLbWx4ZDJya1hXakVlVWszMnQtV1NEdDZwSHpJb3dxWEhXMmxtUmNsM05tRGhiSUhzaGN5d013NlVXLUVMZElxeWVGZU9QLTFSTmRZcy0xQlByMTdfcW0xYXd1VDRBYk9CMy1TazlWa0VWTlBiYUVubkJDc3lvU1lkbTdkZHZJYTVTRnM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (LXEO) director awarded 35,000 stock options at $4.70 strike", "summary": "Lexeo Therapeutics director Reinaldo M. Diaz was granted 35,000 stock options at an exercise price of $4.70 per share as equity compensation. These options will vest on the earlier of one year from the grant date or the next annual stockholders' meeting, conditional on his contin", "url": "https://www.stocktitan.net/sec-filings/LXEO/form-4-lexeo-therapeutics-inc-insider-trading-activity-cc2a4bf91386.html", "source_name": "Stock Titan", "published_at": "2026-06-28T06:40:43", "published_display": "28 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Price Target Cut to $9.00/Share From $12.00 by JP Morgan", "summary": "JP Morgan has adjusted its price target for Lexeo Therapeutics, lowering it from $12.00 per share to $9.00 per share.", "url": "https://www.moomoo.com/news/post/72046425/lexeo-therapeutics-price-target-cut-to-9-00-share-from", "source_name": "Moomoo", "published_at": "2026-06-26T13:08:54", "published_display": "26 Jun 2026 13:08", "sentiment": "negative", "sentiment_pct": 24, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Lexeo Therapeutics, Inc. \u2013 NASDAQ:LXEO", "summary": "This article displays the \"Price to sales forward\" metric for Lexeo Therapeutics, Inc. under the NASDAQ:LXEO ticker. It presents a financial overview of the company on the TradingView platform, showing the period, value, change, and percentage change for this specific financial i", "url": "https://www.tradingview.com/symbols/NASDAQ-LXEO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:39:42", "published_display": "26 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Is Maintained at Overweight by JP Morgan", "summary": "JP Morgan has reiterated its \"Overweight\" rating on Lexeo Therapeutics. The article states that this is a maintenance of a previous rating. No further details about the reasons behind the rating or the company's performance are provided.", "url": "https://www.moomoo.com/news/post/72046428/lexeo-therapeutics-is-maintained-at-overweight-by-jp-morgan", "source_name": "Moomoo", "published_at": "2026-06-26T01:39:29", "published_display": "26 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/lexeo-therapeutics-announces-publication-jama-200100504.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T20:01:00+00:00", "published_display": "17 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Finalizes Study Design for Friedreich Ataxia Gene Therapy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexeo-therapeutics-finalizes-study-design-132952545.html", "source_name": "MT Newswires", "published_at": "2026-06-15T13:29:52+00:00", "published_display": "15 Jun 2026 13:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexeo-therapeutics-announces-regulatory-registrational-110000889.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T11:00:00+00:00", "published_display": "15 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics (Nasdaq: LXEO) maps LX2006 pivotal trial, 2027 data and 2028 BLA bid", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNc0dkc1Q2OS1jUXc1ZUFTTzR1WnpCZnZXMUU2em5JazY3SWIxbW5qbXppUlprN2ZEbG0ydVhHVkdyYWFYeXl3ZkVLMXRWS0lIUVNuUjU1cmNTREdJeDVrT2p1Sk0yS1dMSUhFcElLM2J5N0xJNnltTDY0VTc0bGpUeHVlUlJaRXFRbHZ2bjRTSXptTEVyeEF6R1hVVnVOLXVlR0lKS19VbnNZY19JOUZocw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexeo-therapeutics-participate-2026-rbc-110000578.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T11:00:00+00:00", "published_display": "19 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexeo-therapeutics-reports-first-quarter-110000012.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T11:00:00+00:00", "published_display": "11 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexeo-therapeutics-announces-multiple-presentations-211500887.html", "source_name": "GlobeNewswire", "published_at": "2026-04-27T21:15:00+00:00", "published_display": "27 Apr 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$LXEO stock is up 9% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOendQODZkMnNTSm5BWlQwcFhUcy15MzN4cm56ZzJha1JTUmlja1hIdXUtOEJaVk5mQUhVOFktR2dOMHMxdjdBTGZHWGVCUFY1Z3J5YzhRQ3ZBS0ltVl9PN1JFYjgxd0FvQmlYRWtGakxGMENSVWttTWZudUQwaTB5WTRPZ2FmY0xfSEVYbEFRZFRUT2NwaTRuZFR6Y0VwWWM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn\u2019t the Only Problem.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPMTdzUkZQWG9tTW9zT3FxSWtzdkdLLUNYVkRJMDh2X1VRSlVrdmVkS3FCSVFpX210VUxVSUF1Q2FYakw1ZUxyQlpoZHZpM1RYQzBOYlpEWENxeGM1bXBZNFYxQjZRcFBpcS0tVVhRdzFTejBrVzU3aU9QQXdnYkZBMWxB?oc=5", "source_name": "Barron's", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional investors have a lot riding on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with 56% ownership", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-10T08:00:00+00:00", "published_display": "10 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Announces $80 Million Equity Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgJBVV95cUxQSkZmVWNXWE51TFg4NWwxQnMyVWVmbFdRSnZLZFlNb1RJTU93dXVxbWRfUjg1czhaUzVlRzRUTENjUjNINkE3OWJoWmVYNWZnZkVCaUJEcktNQ2pVUkFnUWRZUm1sSHdqRkNkWEZnWGtkLURlNWpTVlhWdFdpbWlNY3VxVEJ2aVZRd1JCTHoyWmQzYlNlWTNnd0FTRlBLTVNaaXgySm5wdXlJN0s4dlVwQjg0RTJxemNoeW5ieC1qaE5XZDJteEg5RU5YOVhSczJSOEtnYk9uUGJNdGhJS2tIU3ZfcXZzcGRSWkNPUWEtVFd4d3E1cWVVR1pEMUF0UUVGQ3Bzdkc5UmlRTUYySF9PcFlEa012NUdEYU1MOEhOMkIzTm9qVm5Nc1Fsc180RW9NM2NOcGsydFBwbGlhbzJ0WEZTQWRmdw?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-05-27T07:00:00+00:00", "published_display": "27 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNMW54UkNUOTN0ZUlqUF9GcFVxa3pNd2lGTncySXhYYjM3eUJoNUZOYzEtMFUzcmhfOWQzZlg5Q2VReEwxRWNzamxfWGxkaHBzbzEyWjU2ald3VVhkT2UwY0gtRV8zQmlWYi1JbnpTTlJQeEJtR3p0MUNGdVVHQkp3aFFGU2dnc0JTUGVvai00ekVwVlRQNjV2bGd4Wms4alZoWmQ1bUlTcHY3RTR3VXFHSlNfY081YXloZHlIbnlVaw?oc=5", "source_name": "Stock Titan", "published_at": "2024-03-13T07:00:00+00:00", "published_display": "13 Mar 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 85, "total_relevant": 61, "sentiment_summary": {"positive": 10, "negative": 6, "neutral": 45, "score": 52, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 19.6, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 10.19, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 10, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 4.82, "latest_week": "2026-07-10", "one_week_move": 2.8, "four_week_move": 10.3, "twelve_week_move": -30.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.142929, "market_dynamics_buy_signal": false, "relative_strength": -38.374288, "fair_value_gap": -44.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.3095, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.8% over one week, +10.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 15}, {"label": "Market source", "count": 7}, {"label": "GlobeNewswire", "count": 6}, {"label": "Simply Wall Street", "count": 3}, {"label": "Investing.com Canada", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 19}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 2}, {"label": "Deals and strategy", "count": 1}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+2.8% over one week, +10.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple"}], "updated_at": "2026-07-16T14:29:17.701976+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}